By Ethan Covey
The CDC’s Advisory Committee on Immunization Practices (ACIP) has updated its recommendations on the use of serogroup B meningococcal (MenB) vaccines (MMWR Morb Mortal Wkly Rep 2017;66[19]:509-513).
Two MenB vaccines are licensed in the United States for use in patients aged 10 to 25 years: MenB-FHbp (Trumenba, Pfizer) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals). Recently, the FDA announced new dosing and administration guidelines for MenB-FHbp, which now include both